| Ipilimumab for advanced melanoma: A pharmacologic perspective. | |
| | |
MedLine Citation:
|
PMID: 23047236 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Ipilimumab, a fully human anti-CTLA-4 antibody, has been approved for the treatment of unresectable or metastatic melanoma based on its survival benefit demonstrated in randomized phase III studies. The current approved dosing schedule of ipilimumab is 3 mg/kg as a 90-min intravenous infusion every 3 weeks for a total of 4 doses. The immune-mediated mechanism of action of ipilimumab can result in tumor response patterns that may differ from those observed with conventional chemotherapy; therefore, revised response criteria to fully capture the spectrum of responses have been developed and are being prospectively validated. The safety profile of ipilimumab also reflects its mechanism of action and is characterized by immune-related adverse events. Although most of these events are mild, tolerable and reversible, high-grade immune-related adverse events have been observed in 15% of patients and can be potentially life-threatening if not managed appropriately. Guidelines for the management of these events emphasize thorough patient education, vigilant monitoring and prompt intervention with corticosteroids when appropriate. Ongoing research, including evaluation of ipilimumab in the adjuvant setting, investigation of its use in combination with other agents and assessment of alternative doses, will help optimize and expand the use of this innovative treatment. |
| | |
Authors:
|
Van Anh Trinh; Brenda Hagen |
Related Documents
:
|
9372596 - Transdermal iontophoresis of salmon calcitonin can reproduce the hypocalcemic effect of... 10805946 - A study of aminolevulinic acid-induced protoporphyrin ix fluorescence kinetics in the c... 12775446 - Effects of mobile phone radiation on uv-induced skin tumourigenesis in ornithine decarb... 16773736 - Effects of dietary supplementation with clostridium butyricum on the growth performance... 7519976 - 12-lead and continuous ecg recordings of subjects during inpatient administration of sm... 3219486 - Effects of neuropeptides and capsaicin on the canine tracheal vasculature in vivo. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-10-9 |
Journal Detail:
|
Title: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners Volume: - ISSN: 1477-092X ISO Abbreviation: J Oncol Pharm Pract Publication Date: 2012 Oct |
Date Detail:
|
Created Date: 2012-10-10 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9511372 Medline TA: J Oncol Pharm Pract Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Masked mycotoxins: A review.
Next Document: Cetuximab-induced nephrotic syndrome in a case of metastatic rectal cancer.